TEVOGEN BIO HOLDINGS INC (TVGN) Stock Price, Forecast & Analysis
NASDAQ:TVGN • US88165K1016
TVGN Key Statistics, Chart & Performance
The current stock price of TVGN is 0.2775 USD. In the past month the price decreased by -17.53%. In the past year, price decreased by -78.32%.
TVGN Technical Analysis
TVGN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TVGN Forecast & Estimates
7 analysts have analysed TVGN and the average price target is 5.1 USD. This implies a price increase of 1737.84% is expected in the next year compared to the current price of 0.2775.
TVGN Ownership
TVGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 403.74B | ||
| AMGN | AMGEN INC | 16.99 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.83 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TVGN
Company Profile
Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Company Info
TEVOGEN BIO HOLDINGS INC
15 Independence Boulevard, Suite #210
WARREN NEW JERSEY US
Employees: 18
Phone: 16468078832
TEVOGEN BIO HOLDINGS INC / TVGN FAQ
What does TVGN do?
Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Can you provide the latest stock price for TEVOGEN BIO HOLDINGS INC?
The current stock price of TVGN is 0.2775 USD. The price increased by 1.8% in the last trading session.
Does TEVOGEN BIO HOLDINGS INC pay dividends?
TVGN does not pay a dividend.
What is the ChartMill rating of TEVOGEN BIO HOLDINGS INC stock?
TVGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the analyst forecast for TVGN stock?
7 analysts have analysed TVGN and the average price target is 5.1 USD. This implies a price increase of 1737.84% is expected in the next year compared to the current price of 0.2775.
Can you provide the short interest for TVGN stock?
The outstanding short interest for TEVOGEN BIO HOLDINGS INC (TVGN) is 5.52% of its float.